Thermo Fisher Scientific Further Expands Laboratory Plastics Production to Support COVID-19 Testing, Therapies and Vaccines
Thermo Fisher Scientific (NYSE: TMO) is investing over $140 million to expand its laboratory plastics production to meet surging global demand for COVID-19 testing and vaccine production.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Thermo Fisher Scientific (NYSE: TMO) is investing over $140 million to expand its laboratory plastics production to meet surging global demand for COVID-19 testing and vaccine production. The initiative will create more than 1,000 jobs across various locations, including Rochester, NY, and Tijuana, Mexico. The company aims to enhance automation and optimize its supply chain to ensure availability of essential products like pipette tips and storage tubes. This expansion underscores Thermo Fisher's commitment to supporting the ongoing COVID-19 response with crucial laboratory supplies.
Positive
- Investment of over $140 million for facility expansions.
- Creation of more than 1,000 jobs globally.
- Expansion of laboratory plastics production to meet COVID-19 demand.
- Enhancement of automation capabilities and supply chain agility.
Negative
- None.
Details
News Market Reaction – TMO
The recorded move for TMO in the trading session of this news was +0.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass. , Sept. 15, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is investing more than
"Early in the pandemic, we quickly joined forces with governments, public health agencies and industry to increase capacity across our laboratory plastics production facilities and address the growing COVID-19 threat," said Fred Lowery, senior vice president and president of Life Sciences Solutions and Laboratory Products at Thermo Fisher Scientific. "However, demand quickly exceeded those early expansion projects, so we began a series of additional expansions to meet the growing needs of our customers. These investments, along with many others across the company, will ensure that our customers have the supplies they need to continue meeting the unprecedented demands of the COVID-19 response."
The rapid increase in production related to COVID-19 testing, and development and manufacturing of therapies and vaccines, has created historic demand for laboratory plastics, including pipette and automation tips, storage tubes and plates, transfer pipettes, and packaging vials and bottles. To support these needs, Thermo Fisher is creating more than 1,000 jobs across manufacturing sites globally, increasing automation capabilities and optimizing warehouse and sterilization capacity to improve supply chain agility.
Among the Thermo Fisher sites currently being expanded are Rochester, N.Y.; Petaluma, Calif.; Monterrey and Tijuana, Mexico; and Joensuu, Finland.
Thermo Fisher offers an extensive range of laboratory plastics, including Thermo Scientific Nalgene and Nunc plasticware and the Thermo Scientific Manual and Electronic Pipetting Systems. From bottles, beakers, funnels and tubes to pipettes, tips and diagnostic plates, Thermo Fisher consumables support critical COVID-19 work globally and include sample collection vials for diagnostic test kits, pipettes for test processing, lab essentials for research into therapies and vaccines, lab plastics to support clinical and epidemiological studies, and materials for vaccine production and biobanking.
For more information about the Thermo Scientific range of laboratory plastic consumables, please visit www.thermofisher.com/backtothelab.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-further-expands-laboratory-plastics-production-to-support-covid-19-testing-therapies-and-vaccines-301130847.html
SOURCE Thermo Fisher Scientific
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.